Rainer Brachmann
Affiliations: | Washington University, Saint Louis, St. Louis, MO |
Area:
Molecular Biology, Oncology, Cell BiologyGoogle:
"Rainer Brachmann"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dotan E, Cardin DB, Lenz HJ, et al. (2020) Phase 1b study of Wnt inhibitor ipafricept (IPA) with gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic cancer (mPDAC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Moore KN, Gunderson CC, Sabbatini P, et al. (2019) A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology |
| Xu B, Yin Y, Song Y, et al. (2018) Abstract CT050: A phase I dose escalation study of BGB-290 in Chinese subjects with advanced ovarian, fallopian, and primary peritoneal, or advanced triple-negative breast cancer Cancer Research. 78 |
| Kobayashi T, Ishida J, Musashi M, et al. (2011) p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. International Journal of Cancer. 128: 304-18 |
| Wang T, Zeng J, Lowe CB, et al. (2007) Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53. Proceedings of the National Academy of Sciences of the United States of America. 104: 18613-8 |
| Papageorgio C, Brachmann R, Zeng J, et al. (2007) MAGED2: a novel p53-dissociator. International Journal of Oncology. 31: 1205-11 |
| Danziger SA, Zeng J, Wang Y, et al. (2007) Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants. Bioinformatics (Oxford, England). 23: i104-14 |
| Dearth LR, Qian H, Wang T, et al. (2007) Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis. 28: 289-98 |
| Bichutskiy VY, Colman R, Brachmann RK, et al. (2006) Heterogeneous biomedical database integration using a hybrid strategy: a p53 cancer research database. Cancer Informatics. 2: 277-87 |
| Danziger SA, Swamidass SJ, Zeng J, et al. (2006) Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants. Ieee/Acm Transactions On Computational Biology and Bioinformatics / Ieee, Acm. 3: 114-25 |